8-K: Verrica Pharmaceuticals Reports Q1 2026 Results, YCANTH Demand Grows

Verrica Pharmaceuticals announced first quarter 2026 financial results, highlighting record demand for YCANTH and progress in its clinical development programs.

Summary

• Verrica Pharmaceuticals reported total revenue of $5.0 million for the first quarter of 2026.
• U.S. YCANTH net product revenue was $4.3 million, an increase of 16.2% sequentially and 25.4% year-over-year.
• Dispensed YCANTH applicator units reached 15,302 in Q1 2026, up 12.1% from the previous quarter and 51.3% year-over-year, exceeding 100,000 units since launch.
• License and collaboration revenue was $0.7 million, primarily from commercial supply for YCANTH's launch in Japan.
• The company achieved over 50% of targeted enrollment in the first Phase 3 trial for common warts and plans to initiate a second trial in mid-2026.
• Preparation continues for a Phase 3 study of VP-315 for basal cell carcinoma.
• Net loss for the quarter was $9.7 million ($0.45 per share), compared to a net loss of $9.7 million ($1.03 per share) in Q1 2025.
• Non-GAAP net loss was $8.8 million ($0.41 per share) for Q1 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong commercial growth for YCANTH and promising clinical trial progress, despite continued net losses typical for a growth-stage biopharmaceutical company.

Positives

• Record demand for YCANTH with dispensed applicator units growing 12.1% sequentially and 51.3% year-over-year, surpassing 100,000 units since launch.
• YCANTH U.S. net product revenue increased by 16.2% sequentially to $4.3 million.
• Successful commercial launch of YCANTH in Japan by partner Torii Pharmaceutical.
• Significant progress in the common warts Phase 3 program, with over 50% of targeted enrollment achieved in the first trial.
• Initiation of a second Phase 3 trial for common warts in the U.S. and Japan is expected in mid-2026.
• Interest expense decreased significantly by $2.0 million due to the settlement of the company's debt facility.
• The company has retained full commercial rights for YCANTH for common warts outside of Japan, representing a substantial opportunity.
• VP-315 Phase 2 data for basal cell carcinoma is generating strong interest and showing potential abscopal-like effects.

Negatives

• Net loss for the quarter was $9.7 million, consistent with the prior year's net loss.
• Selling, general and administrative expenses increased by $1.2 million to $10.0 million, primarily due to expanded commercial spend.
• Research and development expenses increased by $1.6 million to $3.9 million, driven by the common warts Phase 3 program.
• Cash balance decreased from $30.1 million at the end of 2025 to $20.6 million at the end of Q1 2026.
• Non-GAAP net loss per share increased from $0.88 in Q1 2025 to $0.41 in Q1 2026.

Risks

• The forward-looking statements are based on current beliefs and expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
• Risks include market conditions and other uncertainties described in Verrica's SEC filings.
• The success of YCANTH for common warts and VP-315 for basal cell carcinoma is dependent on successful clinical development and regulatory approvals.
• Expansion into new markets and indications carries inherent regulatory and commercialization risks.

Future Outlook

The company anticipates initiating the second Phase 3 trial for YCANTH in common warts in the U.S. and Japan in mid-2026. Preparations are also underway for a Phase 3 study of VP-315 in basal cell carcinoma. Management believes that successful development and approval of these pipeline programs could represent significant opportunities.

Management Comments

• "Our first quarter performance reflects accelerating growth in market demand for YCANTH as the new standard of care for the treatment of molluscum contagiosum..."
• "As the only FDA-approved, HCP-administered therapy for molluscum, YCANTH is a product that is uniquely positioned to address the unmet need of patients with molluscum, largely children under the age of 14."
• "We have also achieved another significant milestone in expanding to new markets as our partner, Torii Pharmaceutical, launched YCANTH in Japan for patients with molluscum following regulatory approval last year."
• "We are beginning to realize the traction from the efforts we began to implement last year to stabilize and grow our business."
• "We believe Verrica's future growth is enhanced by the potential of our late-stage clinical programs in basal cell carcinoma and common warts, which we believe could represent multi-billion dollar opportunities if these programs successfully complete their development and are approved."
• "The exciting data from the Phase 2 study of our novel oncolytic peptide, VP-315, for the treatment of basal cell carcinoma is generating strong interest within the dermatology and oncology communities and among patients faced with treating basal cell carcinoma."
• "If successful, the global Phase 3 program in common warts has the potential to greatly expand the market for YCANTH to an indication with an estimated 22 million patients in the United States."
• "We are proud of our progress in establishing YCANTH as the new standard of care for molluscum and of our work to expand our products, indications and markets."

Industry Context

StockSavvy.ai notes that Verrica Pharmaceuticals is operating in the competitive dermatology therapeutics market, focusing on unmet needs in conditions like molluscum contagiosum and skin cancers. The company's strategy involves leveraging its approved product, YCANTH, for new indications and advancing its pipeline candidates like VP-315, mirroring industry trends of seeking label expansions and novel treatments for significant patient populations.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if pipeline programs are successful and YCANTH continues to grow market share. Continued investment in R&D and commercialization may impact short-term profitability.
• Patients: Access to YCANTH for molluscum contagiosum and potential future treatments for common warts and skin cancers.
• Employees: Continued growth and investment in commercial and R&D teams.
• Partners (e.g., Torii Pharmaceutical): Collaboration on market expansion and product launches.

Next Steps

• Initiate the second Phase 3 trial (COVE-3) for YCANTH in common warts in the U.S. and Japan in mid-2026.
• Present data from the Phase 2 study of VP-315 at the 2026 Society for Investigative Dermatology (SID) Annual Meeting.
• Continue preparation for the Phase 3 study of VP-315 in basal cell carcinoma.
• Continue commercialization efforts for YCANTH in the U.S. and Japan.

Key Dates

Recommendation

The company shows strong commercial traction for YCANTH and promising pipeline development. However, the continued net losses and the inherent risks in clinical development and market adoption warrant a 'hold' recommendation until further clinical and commercial milestones are achieved.

Keywords

Verrica Pharmaceuticals, YCANTH, molluscum contagiosum, common warts, basal cell carcinoma, VP-315, financial results, Phase 3 trial